JP2022541652A5 - - Google Patents

Info

Publication number
JP2022541652A5
JP2022541652A5 JP2022505261A JP2022505261A JP2022541652A5 JP 2022541652 A5 JP2022541652 A5 JP 2022541652A5 JP 2022505261 A JP2022505261 A JP 2022505261A JP 2022505261 A JP2022505261 A JP 2022505261A JP 2022541652 A5 JP2022541652 A5 JP 2022541652A5
Authority
JP
Japan
Application number
JP2022505261A
Other languages
Japanese (ja)
Other versions
JPWO2021021605A5 (https=
JP2022541652A (ja
JP7644087B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/043415 external-priority patent/WO2021021605A1/en
Publication of JP2022541652A publication Critical patent/JP2022541652A/ja
Publication of JP2022541652A5 publication Critical patent/JP2022541652A5/ja
Publication of JPWO2021021605A5 publication Critical patent/JPWO2021021605A5/ja
Application granted granted Critical
Publication of JP7644087B2 publication Critical patent/JP7644087B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022505261A 2019-07-26 2020-07-24 エンテロウイルスd68に対するヒトモノクローナル抗体 Active JP7644087B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962878955P 2019-07-26 2019-07-26
US62/878,955 2019-07-26
US201962899503P 2019-09-12 2019-09-12
US62/899,503 2019-09-12
US202063047330P 2020-07-02 2020-07-02
US63/047,330 2020-07-02
PCT/US2020/043415 WO2021021605A1 (en) 2019-07-26 2020-07-24 Human monoclonal antibodies to enterovirus d68

Publications (4)

Publication Number Publication Date
JP2022541652A JP2022541652A (ja) 2022-09-26
JP2022541652A5 true JP2022541652A5 (https=) 2023-07-28
JPWO2021021605A5 JPWO2021021605A5 (https=) 2023-07-28
JP7644087B2 JP7644087B2 (ja) 2025-03-11

Family

ID=72039700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505261A Active JP7644087B2 (ja) 2019-07-26 2020-07-24 エンテロウイルスd68に対するヒトモノクローナル抗体

Country Status (6)

Country Link
US (1) US12410241B2 (https=)
EP (1) EP4004037A1 (https=)
JP (1) JP7644087B2 (https=)
KR (1) KR20220038415A (https=)
CA (1) CA3145278A1 (https=)
WO (1) WO2021021605A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172489A1 (en) 2020-03-23 2021-09-30 Amit KHANDHAR Nanoemulsion compositions and methods for delivery of nra
WO2023039064A2 (en) * 2021-09-08 2023-03-16 The Scripps Research Institute Broadly neutralizing antibodies against sars-like viruses
EP4405372A4 (en) 2021-09-22 2026-01-14 Hdt Bio Corp SARS-CoV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE
KR20240096468A (ko) 2021-09-22 2024-06-26 에이치디티 바이오 코포레이션 감염병에 대한 rna 백신
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
WO2023049753A2 (en) * 2021-09-22 2023-03-30 Hdt Bio Corp. Compositions and methods for enhanced antigen binding proteins
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
LU103006B1 (de) * 2022-09-15 2024-03-15 Phaeosynt Gbr Immunoassay zum nachweisen biologisch aktiver proteine
US12435357B2 (en) 2022-12-22 2025-10-07 Kanso Diagnostics Ltd. Diagnostic device for detecting a target nucleic acid molecule in a biological sample
WO2024173657A2 (en) * 2023-02-17 2024-08-22 Vanderbilt University Antibodies to human pneumoviruses and methods of use therefor
CN117805395A (zh) * 2023-12-29 2024-04-02 上海药明合联生物技术有限公司 一种比较抗体偶联药物和抗体的亲和力的方法及其应用
WO2025231143A1 (en) 2024-04-30 2025-11-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against ev-d68
CN118994382B (zh) * 2024-10-25 2025-02-28 南京医科大学 Ev-d68抗体及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
US5563250A (en) 1987-12-02 1996-10-08 Neorx Corporation Cleavable conjugates for the delivery and release of agents in native form
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
CN108794625A (zh) * 2018-06-12 2018-11-13 中国医学科学院医学生物学研究所 一种抗ev-d68病毒的单克隆抗体及其制备和应用

Similar Documents

Publication Publication Date Title
JP2022541652A5 (https=)
CN305529724S (https=)
CN305530516S (https=)
CN305536957S (https=)
CN305536400S (https=)
CN305536077S (https=)
CN305535810S (https=)
CN305535560S (https=)
CN305535511S (https=)
CN305534893S (https=)
CN305580314S (https=)
CN305533529S (https=)
CN305533049S (https=)
CN305532048S (https=)
CN305531846S (https=)
CN305531204S (https=)
CN305531184S (https=)
CN305530406S (https=)
CN305529680S (https=)
CN306562302S (https=)
CN306559800S (https=)
CN306558528S (https=)
CN306551826S (https=)
CN306195992S (https=)
CN306195312S (https=)